Translational Relevance 1
Although HDACi have often been described as preferentially tumor-selective, the underlying 2 mechanism(s) of action remain unclear. Furthermore, their use in the clinic has not always met 3 expectations. By mechanistically addressing HDAC inhibitors preferential tumor-selectivity, our 4 findings suggest c-Myc, and its acetylation and modulation, as markers of HDAC inhibitors 5 response prediction in vitro, ex vivo, in mice and in patients undergoing clinical trials. The potential 6 improved patient stratification could pave the way towards 'personalized' therapies. 7 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44 Introduction 1 Disruption of cellular pathways controlling proliferation and cell death, caused by genetic or 2 epigenetic alterations, is a fundamental event for initiation and progression of cancer (1,2). 3
Alterations in balanced epigenetic networks have been identified in all types of human cancers and 4 involve multiple genes and molecular pathways. Changes in the epigenome comprehend several 5 types of covalent modifications of DNA and associated proteins. The best-studied changes include 6 modifications of the amino-terminal ends of core histones and methylation of cytosines in DNA. 7
The mechanisms that drive epigenetic silencing in pre-malignant cells are, however, still rather 8 elusive. Recent studies have suggested that one of the first steps in tumorigenesis may be epigenetic 9 inactivation of genes altering the normal pathways of cell proliferation, differentiation and death 10 (3). Unlike genetic mutations, epigenetic modifications are potentially reversible allowing the 11 malignant cell population to revert to its initial state. With the advent of numerous drugs acting on 12 specific enzymes involved in the epigenetic regulation of gene expression, targeting the epigenome 13 is emerging as an effective and valid approach complementary to chemotherapy as well as 14 chemoprevention of cancer, raising the possibility of epigenetic therapies. The re-expression of 15 epigenetically inactivated genes can result in the suppression of tumor growth or sensitization to 16 anticancer therapies. It is now well established that epigenetically silenced genes may be reactivated 17 pharmacologically by the action of small molecules ('epidrugs') able to correct epigenetic defects. One key problem with anticancer drugs is their lack of tumor specificity. Identifying genes that are 1 differentially expressed in cancer cells compared to normal cells is likely to provide valuable 2 information for customized treatment. We (and others) have previously demonstrated that the 3 treatment of acute myeloid leukemia (AML) with HDACi is linked to re-expression of TRAIL and 4 induction of apoptosis (10-12). The tumor necrosis factor-related apoptosis-inducing ligand 5 (TRAIL) induces apoptosis via 2 death receptors, death receptor 4 (DR4/TRAIL-R1) and 5 6 (DR5/TRAIL-R2), expressed on the cell membrane. Upon binding, apoptosis is rapidly triggered in 7 a variety of human cancer cell lines but not in normal cells. This property makes TRAIL one of the 8 promising novel bio-therapeutic agents for cancer therapy (13). However, the potential applications 9 of TRAIL are limited since many primary cancer cells are resistant, generally due to defects in 10 transduction of apoptotic signal of TRAIL-R. Several studies have employed strategies to boost the 11 sensitivity of tumor cells to TRAIL, based on the combined administration of TRAIL with different 12 drugs such as proteasome inhibitors, HDACi, and kinase inhibitors (14-17). 13
In light of the vastly differential cell responsiveness to TRAIL, it is crucial to identify and 14 characterize biomarkers for sensitivity to this ligand. Ashkenazi Heidelberg, Germany) antibodies were used. ChIP assays were performed as previously described 8 (12). See also Supplementary Methods and Table S2 . 9
10
Luciferase reporter assay, siRNA and shRNA 11 pTRL were previously described (12). Plasmids for c-Myc and its phosphorylation mutants were 12 kindly provided by H. Gronemeyer; MYC-K323 mutants (Q or R) were produced for this study. In 13 MCF7 cells, siRNA was obtained from Dharmacon (Ladayette, CO, USA). MISSION shRNA 14 target set by Sigma-Aldrich was used. pLKO.1-puro and pLKOshMyc plasmids were used 15 according to manufacturer's instructions. See also Supplementary Methods. 16
17

Apoptosis and cell cycle 18
Apoptosis and cell cycle analysis were performed as in (26) . 19
20
Immunoprecipitation assay 21
Immunoprecipitation assay was performed as in (27) . 22
23
In vivo mouse studies 24 PML-RARα APLs in the C57Bl/6 background were described previously (28) and in 25 Supplementary Methods. 26 1
Results
2
Modulation in c-Myc expression is a signature of HDAC inhibition in AML cells 3
In order to identify a core set of HDACi-regulated genes and to provide a rationale for novel 4 biomarkers useful in clinical practice, gene expression analyses were performed (Fig. 1) . K562, 5 U937 and NB4 AML cell lines were treated with two clinically advanced HDACi, SAHA and 6 MS27-275, and gene expression profiles were analyzed in response to 6-hour treatment. 7
Bioinformatic analysis revealed overlap in the genes altered in expression following treatment with 8 the two HDACi within each cell line (Fig. 1A) as well as cell line-specific responses. In the three 9 AML cell lines, 319 and 215 genes were commonly modulated by SAHA and MS27-275, 10 respectively, and 154 genes were modulated by both HDACi. Importantly, a comparative gene 11 expression analysis between the 154 common set derived from AML cell lines and 3 primary blasts 12 of AML patients treated ex vivo with SAHA showed a set of 6 commonly modulated genes, which 13 we refer to as the core (Fig. 1B) . It includes increased CRISPLD2 and TUFT1, and decreased 14 MYB, MYC, PHFIS and RGS19. The well-known oncogenic properties of c-Myc, including its 15 ability to recruit HAT/HDAC complexes (29), make it the most intriguing. Expression levels of the 16 6 core regulated genes were also evaluated in 2 CD34 + normal progenitors treated with SAHA and 17 then compared with those of AML cell lines and blasts. This comparison showed that all genes were 18 similarly regulated by SAHA in CD34 + except for c-Myc, which was only marginally affected by 19 the treatment in the normal progenitors (Fig. 1B, right panel) . 20
These data indicate that c-Myc might play a role in the tumor-specific action of HDACi in AML 21 (11, 12) . quantitative PCR ( Fig. 2A-B) revealed the presence of c-Myc on the TRAIL promoter in untreated 7 conditions and its displacement after only 30 minutes and 4 hours of treatment with SAHA and 8 MS27-275, respectively. Given that non-canonical E-boxes are found on the TRAIL promoter 9 regulatory region and that 2 GC boxes on the TRAIL promoter are essential in its regulation by 10 HDACi (12), c-Myc binding might be mediated by multi-protein complexes targeting GC boxes. 11
Moreover, both HDACi displayed a strong inhibitory effect on c-Myc expression at mRNA (Fig.  12 2C and Supplementary Fig. S1A ) and at protein levels (Fig. 2D) . (Fig. 2E ). In agreement with our previous study 5 (12), mutations in the promoter proximal GC box of TRAIL completely abrogated SAHA and c-6
Myc responsiveness, but did not affect basal levels, whereas mutations in the distal GC box reduced 7 basal activity, but maintained substantial SAHA induction and c-Myc responsiveness (Fig. 2E,  8 upper right). The fact that the two phosphorylation mutants c-Myc T58A and c-Myc S62A were still able 9 to block TRAIL activation suggests that the role of phosphorylation of c-Myc at the conserved 10 residues serine 62 (S62) and threonine 58 (T58) is marginal in these settings (Fig. 2E, lower right) . 11
Further supportive evidence for c-Myc-induced repression of basal levels of TRAIL promoter as 12 well as its induction by HDACi was obtained by Western blot analyses. A negative correlation 13 between c-Myc and TRAIL expression was observed in three different cell lines (NB4, HL60 and 14 U937) (Fig. 2F, upper panel) . Moreover, siRNA-mediated reduction of c-Myc in MCF7 cells 15 resulted in an increase in TRAIL protein levels (Fig. 2F, lower panel) . In accordance, we observed a 16 higher induction of TRAIL in stably infected sh-c-Myc than control U937 cells after HDACi 17 treatment and an increased TRAIL basal expression level (Fig. 2G) . In agreement and as expected, 18 the growth rate of cells expressing sh-c-Myc was visibly altered when compared to sh-CTRL (Fig.  19   2H) . Conversely, c-Myc overexpression increased both the capability to form colonies in semisolid 20 medium and SAHA responsiveness ( Supplementary Fig. S2A ). c-Myc down-regulation and TRAIL 21 induction by HDACi were not dependent on p21 expression ( Supplementary Fig. S2B ). Notably, 22
TRAILshRNA showed reduced basal level of c-Myc and the HDACi-mediated down-regulation 23 was no longer detected ( Supplementary Fig. S2C ). Furthermore, DR5 and p21 WAF1 expression 24 levels and their induction after HDACi treatment were also increased, demonstrating that these 25 Collectively, the data show that c-Myc binds to TRAIL promoter via the proximal GC box, 3 supporting our hypothesis. Furthermore, it may be speculated that responsiveness to SAHA is 4 influenced by c-Myc-TRAIL modulation. 5 6
HDACi treatment unlocks TRAIL transcription 7
Given that TRAIL promoter region may be repressed by c-Myc, we decided to investigate its 8 epigenetic status. We performed quantitative ChIP assays to identify changes in histone H3 and H4 9 modifications at various loci across the TRAIL promoter region in U937 cells ( Supplementary Fig.  3   S6C) . Furthermore, c-MycK323ac was readily detectable already after 1 hour of SAHA treatment in 4 U937 cells (Fig. 5A) . 5
Interestingly, c-MycK323 acetylation was inversely proportional to HDACi-mediated down-6 regulation by c-Myc ( To corroborate our data, c-Myc levels and their correlation with TRAIL expression was also 24 evaluated in 21 primary blasts derived from AML patients (Fig. 6A) . In all cases the relative protein 25 levels of TRAIL and c-Myc were inversely correlated. In untreated conditions, c-Myc and TRAIL 26 levels were high and low, respectively. Already after 24 hours of SAHA treatment, c-Myc mRNA 1 levels were strongly decreased, while TRAIL transcript levels were up-regulated. TRAIL induction 2 led to strong apoptosis, revealed as a percentage of cells in pre-G1 phase. 3 Excitingly, c-Myc deregulation by SAHA treatment was accompanied by its acetylation in ex vivo 4 blasts, as representatively illustrated (Fig. 6B) . Levels of c-Myc and its acetylated K323 form were 5 not modulated by HDACi treatment in normal myeloid CD34 + progenitors in which basal levels of 6 c-MycK323ac were present ( Supplementary Fig. S8A-B) . Similarly, c-FLIP mRNA levels resulted 7 unaltered, supporting HDACi incapability to elicit cell death in normal systems (Supplementary 8 To corroborate and extend our data, c-Myc expression levels were evaluated in a group of 23 AML 1 patients included in a phase II trial of SAHA with idarubicin and cytarabine (Fig. 6F ). An 2 evaluation of safety and efficacy of the study was previously published (2). The aim of this trial, the 3 so-called IA program, was to test the efficacy of SAHA treatment in combination with standard 4 chemotherapy for AML patients at the MD Anderson Cancer Center. Specifically, SAHA was 5 administered orally 3 times a day at a dose of 500 mg on days 1 to 3; on day 4 idarubicin was 6 administrated at a dose of 12 gm/m2/day for 3 days with cytarabine at a dose of 1.5 gm/m2/day as 7 continuous infusion for 4 days. One cycle of therapy lasted 28 days. 8
Notably, in 14 patients, c-Myc expression decreased after 3 days of treatment with SAHA alone, 9
providing a response prediction. The majority of patients displayed c-Myc down-regulation at day 10 7, although the greatest response was obtained at cycle end (day 28). Importantly, one therapy non-11 responder was a patient harboring chromosome 8 mutations on which the c-Myc gene resides. 12
Taken together, these data support the hypothesis that c-Myc (and its acetylated K323 form) tumor-13 specifically regulates TRAIL expression ex vivo and in AML patients, predicting epi-treatment 14 response. Strengthening the predictive role of c-Myc to HDACi responsiveness, c-Myc, c-15
MycK323ac and TRAIL expression levels were evaluated in an APL mouse model (28) (Fig. 6G) . 16
Survival studies on the mice after 27-days exposure to VPA were previously reported (28) revealed that they have 6 deregulated genes in common (Fig. 1) . These 6 genes may represent the 12 conserved signature between AML cell lines and blasts after HDACi treatment. Interestingly, when 13 testing the responsiveness of these genes to HDACi in CD34 + normal cells, c-Myc gene expression 14 was most differentially regulated. In normal progenitors c-Myc was slightly -if at all -deregulated 15 while both in AML cell lines and primary blasts it was highly down-regulated. 16
c-Myc appears to play a repressive role in TRAIL induction in untreated AMLs since its 17 overexpression (Fig. 2F) and silencing (Fig. 2F-G HDACi treatment (Fig. 2E) . Supporting the role of c-Myc in marking HDACi response, c-Myc-20 silenced cells responded weakly to HDACi treatment, displaying an 'initially impaired' growth rate, 21 likely due to TRAIL re-expression levels. Interestingly, although TRAIL expression was low in 22 AML cells, active epigenetic marks at the TRAIL promoter (33), such as H3K4me1, 2, 3, are 23 strongly present (Fig. 3, Supplementary Fig. S4 and Table S1) promoter likely occurs via the proximal GC box, which is a binding site for Sp1/Miz1. We 1 previously showed that this cis-acting element is crucial for HDACi-mediated TRAIL activation 2 (and other apoptotic genes) (12,32,33). As c-Myc resides on the TRAIL promoter regulatory region 3 ( Fig. 2A-B) and binds Sp1/Miz1 (Fig. 4) , we may conclude that c-Myc mediates TRAIL regulation 4 via the proximal GC box. In this scenario, the Myc-Max dimer strongly represses TRAIL and is 5 displaced upon HDACi treatment, thus allowing transcriptional action of Sp1 (47). It is thus 6 tempting to speculate that this type of (de)regulation is a common mechanism for HDACi-7 responsive genes, as supported by the similar behavior of DR5 and p21 (Supplementary Fig. S3) . Based on these data, several hypotheses may be formulated. Firstly, c-Myc deregulation in cancer 21 acts both pro-proliferatively by direct binding to E-box-containing promoters, and as a suppressor 22 of apoptosis via Sp1/Miz1-residing factors on GC boxes. Secondly, HDACi restore normal 23 regulation by decreasing c-Myc levels and reactivating pro-apoptotic pathways in cancer. Thirdly, 24 c-Myc acetylation triggered by HDACi alters c-Myc stability ( Fig. 5D and Supplementary Fig.  25 S1B-D). In support of the third hypothesis, K323, one of the predicted acetylation sites on c-Myc 26 (48), was specifically acetylated after 1 hour (Fig. 5) . c-MycK323ac occurs in many other cancer 1 cell lines upon treatment with HDACi, but not with SIRTi ( Supplementary Fig. S6B ). Given that 2 HDAC1 and 2 have previously been found to reside at the TRAIL promoter (12), c-Myc acetylation 3 likely occurs by HDACi-mediated modification of the binding (and possibly stability) of the c-Myc-4
Max complex on the Sp1 and/or Miz1 factor present on TRAIL chromatin. Extending and 5 corroborating this hypothesis, c-MycK323ac was found to be inversely proportional to c-Myc 6 occupancy on the TRAIL promoter. Significantly, no c-Myc occupancy was found at the intron 7 level (Fig. 5C) . Overall, this model is consistent with the observation that active chromatin marks 8 are associated with the majority of c-Myc target-promoters (49). Hence, c-Myc may block TRAIL 9 expression in a steady state, which can be easily re-activated by HDACi. Inverse c-Myc/TRAIL 10 gene expression was detected in a statistically valid number of ex vivo AML blasts and, as an 11 example of solid cancer, in an ex vivo breast cancer, corroborating this hypothesis. Specifically, this 12 finding shows that in AML blasts, c-Myc-dependent TRAIL silencing is a common event and that 13
HDACi-induced apoptosis correlates with decreased c-Myc levels upon HDACi treatment (Fig.  14   6A) . 15 We speculated that our findings (Fig. 1) suggest a differential action of HDACi on c-Myc 16 expression. In turn, c-MycK323ac might serve as a marker of response prediction and explain the 17 opposite effect of HDACi in cancer and normal cells. In CD34 + normal myeloid progenitors, levels 18 of c-Myc (and c-MycK323ac) are present at a lower level, but are not modulated by HDACi (Fig.  19 6B and Supplementary Fig. S8 ), highlighting that c-Myc down-regulation and acetylation may 20 contribute to the tumor specificity of HDACi in AMLs. Notably, K323 acetylation seems to affect 21 stability of the c-Myc protein only when hyper-induced as in AMLs, suggesting that over-22 acetylation might cause reduced protein stability while preserving stability in normal conditions 23 (50,51) (Fig. 6B) . 24 We therefore hypothesized a model to explain the differential response of normal and cancer cells 25 to HDACi (Fig. 6H and Supplementary Fig. S8 ). In AMLs (or cancer in general) overexpressing c-26 clinical trial (ClinicalTrials.gov Identifier: NCT00656617) with SAHA followed by standard 6 chemotherapy showed a similar decrease in c-Myc and an increase in TRAIL expression (Fig. 6F) . 
